ClinicalTrials.gg
RecruitingNCT06607757Updated Apr 2, 2025

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

A Phase 2 interventional study of Capivasertib and Fulvestrant injection in CCCA Assessed by Ki67 Drop Below <2.7% From Baseline, sponsored by GBG Forschungs GmbH. Recruiting at 25 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by GBG Forschungs GmbH · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a multicenter, prospective, open-label, randomized phase II study to evaluate the CCCA assessed by Ki67 drop below \<2.7% from baseline to week 2 (window of opportunity) and to week 10 with capivasertib plus fulvestrant compared with fulvestrant alone as neoadjuvant treatment for primary high-risk lobular breast cancer patients.

120 patients will be randomized to receive:

  • Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant)

or

  • Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations) Treatment will be given until surgery/core-biopsy, disease progression, unacceptable toxicity, or withdrawal of consent of the patient.

All patients will undergo core-biopsies, under treatment and after completing study therapy in order to assess Ki67%. Further treatment including surgery, (neo)adjuvant chemotherapy, radiotherapy, and (neo)adjuvant endocrine therapy will be administered at the discretion of the investigator and according to standard of care outside the clinical trial.

Read the detailed description

The evaluation of CCCA in the HR+/HER2- invasive lobular breast cancer patient population allows assessment of treatment efficacy with an achievable sample size of HR+/HER2- breast cancer patients within an acceptable and scientifically meaningful duration of recruitment. CCCA can be assessed immediately after last patients end of treatment. Central blinded pathological assessment of CCCA is planned in this study as a standardized preparation of the sampled tissue by the central pathologist. This pathologist is blinded regarding the study therapy administered, i. e. with or without capivasertib.

The addition of capivasertib to fulvestrant in many clinical trials correlates with an improvement in PFS compared to fulvestrant alone in patients with HR+/HER2- locally advanced or metastatic breast cancer. This effect was observed regardless of a PI3K/AKT/mTOR pathway activation. None of the ongoing studies investigate the effects of the combined treatment in invasive lobular breast cancer. Given that these tumors are less likely to respond to chemotherapy, identification of patients that can be spared from chemotherapy is desirable. On the other hand, it is important to identify patients with invasive lobular breast cancer not responding to neoadjuvant ET who might be at increased risk for recurrence, who would therefore potentially benefit from further adjuvant therapies including chemotherapy.

Given the high rates of PI3K pathway alterations in such tumors, it is expected that the CCCA rate could be increased by adding capivasertib to fulvestrant. GBG expect that the potential benefit of improved CCCA rate with a combination treatment compared to fulvestrant monotherapy would outweigh the potential risks due to added toxicity, which has already been shown in clinical trials to be well tolerated by patients.

02

Conditions studied

  • CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
03

In context

Lead sponsor

GBG Forschungs GmbH is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and followup, and documented according to the local regulatory requirements.
  2. women with age at diagnosis ≥ 18 years.

    Postmenopausal status is defined as:

    • Age ≥60 years
    • Age \<60 years and amenorrhea for at least 12 continuous months with no identified cause other than menopause
    • Bilateral oophorectomy Negative pregnancy test (urine or serum) within 14 days prior to randomization for all postmenopausal women 50 years of age or younger without bilateral oophorectomy
  3. Unilateral or bilateral primary untreated lobular invasive carcinoma of the breast. In case of bilateral breast cancer, both sides must be lobular; the lead tumor has to be defined by the investigator based on the inclusion criteria for the respective subtype and the risk status. Lobular histology has to be centrally confirmed.
  4. Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE) tissue block from core before the start of therapy.
  5. Centrally confirmed -negative (IHC score 0-1+ or ISH negative according to ASCO/CAP guideline) and HR-positive (≥10% positive stained cells) disease, assessed on the core of diagnostic biopsy. Ki67% >10% is required. In case of bilateral breast cancer, HER2-negative, HR-positive and lobular histology status has to be confirmed for both sides.
  6. Patients with invasive lobular breast cancer at high risk for recurrence defined as cT1c and clinical nodal involvement (cN+) or ≥ cT2 disease (irrespective of nodal involvement).
  7. No clinical evidence of distant .
  8. (ECOG) performance status (PS) 0 or 1.
  9. Estimated of at least 5 years irrespective of the diagnosis of breast cancer.
  10. The patient must be accessible for scheduled visits, treatment, and followup.
  11. Normal cardiac function must be confirmed according to local guidelines.
  12. Laboratory requirements:

    Hematology

    • (ANC) ≥1.5 x 109 / L
    • ≥100 x 109 / L
    • ≥10 g/dL (≥6.2 mmol/L) Hepatic function
    • Total \<1.25x
    • and ALT \<=1.5x ULN
    • Alkaline phosphatase \<=2.5x ULN Glucose Metabolism
    • \<8.0% (63.9 mmol/mol) Renal Function
    • Creatinine \<1.25x ULN or ≥50 ml/min (if creatinine is above ULN according to Cockroft-Gault)
  13. Complete staging work-up prior to the initiation of neoadjuvant therapy as per standard recommendations.

Exclusion criteria

Exclusion Criteria:

  1. Female patients of .
  2. Excisional or lumpectomy performed prior to study entry.
  3. Surgical axillary staging procedure including sentinel lymph node biopsy prior to randomization. Exceptions: FNA or core biopsy of an axillary lymph node.
  4. Any previous treatment including endocrine therapy, chemotherapy, radiotherapy or targeted therapy (including AKT inhibitor or PIK3 inhibitor) for the currently diagnosed breast cancer.
  5. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer.
  6. Known reaction to one of the compounds or substances used in this protocol.
  7. Potent inhibitors or inducers of within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort).
  8. nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib.
  9. Any for fulvestrant.
  10. Patients with definitive clinical or radiologic evidence of stage IV cancer ( disease) are not eligible.
  11. Patients with a history of any are ineligible with the following exceptions:

    • Patient has been disease-free for at least 5 years and is at low risk for recurrence of that malignancy except for breast cancer.
    • CIS of the cervix, basal cell and squamous cell carcinomas of the skin.
  12. History of type I or type II diabetes mellitus requiring insulin.
  13. Severe and relevant co-morbidity that would interact with the application of study drugs or the participation in the study, including cerebrovascular incident including , or symptomatic pulmonary embolism, active infection requiring intravenous anti-microbial treatment (antibiotics, anti-fungal, and anti-viral drugs) within 1 week of enrolment. Patients with confirmed Gilbert's syndrome may be included in the study.
  14. Known medically history of infection, tuberculosis, or .
  15. History of and/or active cardiac disease that would preclude the use of study treatments. This includes but is not confined to any of the following cardiac criteria:

    • cardiac dysfunction including heart failure ( II-IV), active ventricular arrhythmias requiring medication or arrhythmias requiring a pacemaker, and history of a myocardial infarction within 6 months prior to randomization, angina pectoris, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, angioplasty, or vascular stent.
    • Mean resting corrected by Fridericia's formula (QTcF) >470 msec obtained from 3 consecutive ECGs.
    • Increased risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled electrolyte disorders (e.g., hypocalcemia, hypokalemia, or hypomagnesemia), potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval.
  16. Receipt of within 30 days prior to study entry or within 30 days of receiving therapy.
  17. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of .
  18. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension or hypotension (BP \<50mmHg), significant aneurysm, renal transplant and active bleeding diseases).
  19. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  20. Participation in another clinical study with a study intervention or medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm A

    Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant)

    Drug: Capivasertib · Drug: Fulvestrant injection

  • Active comparator
    Arm B

    Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations)

    Drug: Fulvestrant injection

Interventions

06

What researchers measure

Primary outcomes

  1. To assess complete cell cycle arrest (CCCA).

    The primary endpoint CCCA is defined as Ki67 drop to \&lt;2.7% after approximately 10 weeks (will be assessed centrally on the breast tissue submitted to central pathology)

    Time frame: Up to 14 weeks

Secondary outcomes

  1. To asses safety and tolerability

    Tolerability and safety analyses include assessment of patients whose treatment had to be dose reduced, delayed or permanently stopped.

    Time frame: Up to 14 weeks

  2. To assess patholgogical complete response rate (pCR) by different definitions

    Pathological complete response (pCR ypT0 ypN0) is defined as no microscopic evidence of residual invasive and non-invasive viable tumor cells in all resected specimens of the breast and axilla.

    Time frame: Up to 14 weeks

  3. To assess breast conservation rate (BCS)

    BCS is defiened as tumorectomy, segmentectomy or quandrantectomy as the most radical surgery.

    Time frame: Up to 14 weeks

  4. To assess invasive disease-free survival (iDFS) and overall survival (OS)

    iDFS is defined as time from randomization until first iDFS event OS is defined as time from randomization until death due to any cause

    Time frame: through study completion, an average of 2 years

07

Study locations

9 of 25 sites recruiting
  • Haematologie-Onkologie im Zentrum MVZ GmbH
    Augsburg, 86150, Germany
    Recruiting
  • Charité
    Berlin, 10117, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR
    Bielefeld, 33604, Germany
    Recruiting
  • Hämato-Onkologie im Medicum - Onkologie und Hämatologie
    Bremen, 28209, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Carl-Thiem-Klinikum gGmbH - Frauenklinik
    Cottbus, 03048, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kath. St. Paulus GmbH - Klinische Forschung
    Dortmund, 44137, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Essen - Klinik für Frauenheilkunde und Geburtshilfe
    Essen, 45147, Germany
    Recruiting
  • Klinikum Frankfurt Höchst GmbH - Klinik für Gynäkologie und Geburtshilfe
    Frankfurt am Main, 65929, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Praxis für Interdisziplinäre Onkologie & Hämatologie
    Freiburg im Breisgau, 79110, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Mammazentrum Hamburg - am Krankenhaus Jerusalem
    Hamburg, 20357, Germany
    Recruiting
  • Universitätsklinikum des Saarlandes - Frauenklinik
    Homburg, 66424, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Kassel GmbH - Frauenklinik
    Kassel, 34125, Germany
    Not yet recruiting
  • Kliniken der Stadt Köln GmbH - Brustzentrum Köln-Holweide
    Köln, 51067, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St. Elisabethen-Krankenhaus gGmbH - Senologie / Brustzentrum
    Leipzig, 04277, Germany
    Recruiting
  • Medizinisches Versorgungszentrum MediaVita GmbH Muenster
    Münster, 48145, Germany
    Recruiting
  • Klinikum Oldenburg AöR - Universitätsklinik für Innere Medizin - Onkologie
    Oldenburg, 26133, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MVZ für Hämatolgie und Onkologie Ravensburg GmbH - Studienzentrum
    Ravensburg, 88212, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Südstadt - Universitätsfrauenklinik
    Rostock, 18059, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Leopoldina-Krankenhaus der Stadt Schweinfurt - Frauenklinik
    Schweinfurt, 97422, Germany
    Recruiting
  • Johanniter-Krankenhaus Genthin-Stendal - Klinik für Frauenheilkunde und Geburtshilfe
    Stendal, 39576, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kreiskrankenhaus Torgau - Gynäkologie
    Torgau, 04860, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Praxisnetzwerk Haematologie und internistische Onkologie Ueberoertliche Berufsausuebungsgemeinschaft - Hämatologie und Onkologie
    Troisdorf, 53840, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Marienhospital Witten - Brustzentrum
    Witten, 58452, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum Worms gGmbH - Frauenklinik
    Worms, 67550, Germany
    Recruiting
  • Helios Klinikum Wuppertal GmbH - Landesfrauenklinik
    Wuppertal, 42283, Germany
    Recruiting
08

References and documents

Publications

  • Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5. PubMed 39241495 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jun 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2024
First posted
Sep 23, 2024
StartActual
Dec 4, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Aug 31, 2026
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607757
Lead sponsor
GBG Forschungs GmbH
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Dec 4, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Apr 2, 2025

Study contacts

Christina Müller-Weisbrod
Contact
LOBSTER@gbg.de
+49610274800
Sibylle Loibl, Prof. Dr. med.
principal investigator · ESMO, ASCO, AGO Kommission Mamma (member); Goethe University Frankfurt; GBG Forschungs GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion